<DOC>
	<DOC>NCT00839163</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety and efficacy of the licensed drug enoxaparin and a licensed oral vitamin K-antagonist and to find the optimal dose of BAY59-7939 for the anticipated phase III trials and for the future clinical use.</brief_summary>
	<brief_title>Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Patients with acute symptomatic proximal deep vein thrombosis Contraindication to comparator drugs Symptomatic Pulmonary embolism Conditions with increased bleeding risk Unstable patients with reduced life expectancy Severe renal impairment Impaired liver function Strong CYP 3A4 inhibitors Platelet aggregation inhibitors (exception: ASA up to 500mg) therapy with anticoagulants or fibrinolytics NSAIDs with halflife &gt; 17 hours</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Embolism and Thrombosis</keyword>
	<keyword>Pulmonary embolism</keyword>
	<keyword>Embolism</keyword>
	<keyword>Thrombosis</keyword>
</DOC>